Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

Journal of Clinical Oncology

Volumn 20, Issue 9, 2002, Pages 2251-2266

  Pecora, Andrew L ^a   Rizvi, Naiyer ^a   Cohen, Gary I ^a   Meropol, Neal J ^a   Sterman, Daniel ^a   Marshall, John L ^a   Goldberg, Stuart ^a   Gross, Peter ^a   O'Neil, James D ^a   Groene, William S ^a   Roberts, M Scot ^a   Rabin, Harvey ^a   Bamat, Michael K ^a   Lorence, Robert M ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; ORAL ANTIDIABETIC AGENT; PV 701; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG INDUCED DISEASE; FATIGUE; FEMALE; FEVER; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; VIRUS REPLICATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEWCASTLE DISEASE VIRUS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0036569510     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.042     Document Type: Article

References (49)

1. PV701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts
2. Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus
3. Replication-competent, oncolytic Newcastle disease virus for cancer therapy
4. Scientific interest in Newcastle disease virus is reviving
5. Newcastle disease virus
6. Newcastle disease and other avian paramyxoviruses
7. Newcastle disease virus selectively kills human cancer cells
8. Immunization with virus-modified tumor cells
9. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells
10. Newcastle disease virus activates macrophages for anti-tumor activity
11. Selective replication of Newcastle disease virus in cancer cells is associated with virus-induced cell fusion
12. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
13. The interferon system: A review with emphasis on the role of PKR in growth control
14. How cells respond to interferons
15. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): Mechanism of action
16. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy
17. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
18. Newcastle disease virus as an antineo-plastic agent
19. Treatment of stage II malignant melanoma patients with Newcastle disease virus oncolysate
20. A 15-year follow up of AJCC stage III malignant melanoma patients treated post-surgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
21. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
22. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
23. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
24. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity
25. A phase I and pharmacokinetic study of intravenous (IV) p53 gene therapy with RPR/INGN-201 in patients (pts) with advanced cancer
26. Tumour lysis as a factor affecting blood levels of CEA
27. Systemic administration of replication-selective adeno-viruses
28. Replicating vectors for gene therapy
29. Clinical studies employing interferon inducers in man and animals
30. Reactions of human sera to avian adeno-viruses and Newcastle disease virus
31. Newcastle disease virus antibodies in human sera
32. Quality control of vaccines
33. Mouse genotype affects inducible expression of cytokine genes
34. Circulating interferon in mice after intravenous injection of virus
35. Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid
36. Interleukin-6 release by rat liver macrophages
37. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-α and augmentation of its cytotoxicity
38. Renal cell cancer
39. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity
40. Biologic therapy with TNF: Systemic administration and isolation-perfusion
41. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer
42. Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma
43. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
44. Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma
45. Clinical toxicity of interferons in cancer patients: A review
46. Assessment of liver function
47. Clinical enzymology